AstraZeneca says Fasenra fails to meet one trial endpoint
By Frank Prenesti
Date: Tuesday 25 Oct 2022
(Sharecast News) - AstraZeneca said its Fasenra treatment for a rare inflammatory disease of the oesophagus failed to meet one of the two dual-primary endpoints in a phase 3 trial.
Fasenra demonstrated a statistically significant improvement in histological disease remission, but not a change in dysphagia symptoms, compared to placebo, in patients with Eosinophilic oesophagitis (EoE) aged 12 or older.
EoE is a rare, progressive, chronic inflammatory disease of the oesophagus currently believed to be characterised by the abnormal presence of eosinophils, a type of white blood cell, in the inner lining of the esophagus. Patients experience difficulty with swallowing (dysphagia), pain, food getting stuck and anxiety.
Reporting by Frank Prenesti for Sharecast.com
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN